Use access key #2 to skip to page content.
$11.85 -0.30 (-2.47%)
7/3/2008 1:05 PM

Mylan Laboratories, Inc. (MYL)

CAPS Rating:
****

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MYL

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

374 Outperforms
27 Underperforms
 

All-Stars

104 Outperforms
7 Underperforms
 

Wall Street

13 Outperforms
1 Underperforms
 

Players bullish on MYL are also bullish on:

Players bearish on MYL are also bearish on:

Ticker Tags

Mid Cap (670), S&P 500 (482), Drugs - Generic (14)
Suggest a tag

Mylan Laboratories, Inc. At A Glance

Current Price: $11.85
Last Trade Time: 7/3/2008 1:05 PM
Open: $0.00
Previous Close: $12.15
Daily Range: $11.78 - $12.22
52-Week Range: $10.04 - $18.28
Volume: 3,672,318
Market Cap: $3.70B
P/E Ratio: 11.06
Compare Our Special Broker Offers!

Stock Trends

MYL VS S&P 500 (SPY)

MYL 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

2

Mylan Laboratories, Inc. (MYL)

Avatar caidencollett07 (99.74) Submitted: 3/27/08 3:57 PM

Reasonable Price, I expect a gain in the generic drug industry.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

3

Mylan Laboratories, Inc. (MYL)

Avatar DouglasRich (< 20) Submitted: 1/29/08 9:30 AM

Mylan is known for making good quality, reliable generic pharmaceutical products, but I think their primary drawback is they haven't found a way to outcompete the generic market. In the pharmacy, cheaper generics are preferred to Mylan's oftentimes more expensive products. Teva and Dr. Reddy are t...More

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 81 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (MYL)

Avatar slee99 (< 20) Submitted: 6/29/08 12:41 AM : Outperform Start Price: $12.15 MYL Score: -1.20

Recent large acquisition has saddled them w/large debt and has not achieved synergies and efficiencies yet. Was necessary to achieve size to compete globally and benefits of the merger should become evident in the coming year. Their technical expertise in formulation is their "wide moat." They're in an great sector with many blockbuster drugs coming off patent in next several years, and many countries looking to increase utilization of generic drugs. Downside is their debt burden, but if they're not hit with a major problem in the next year or so, they have a good chance of doubling in 3yrs.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYL)

Avatar jlmjlm77 (29.51) Submitted: 6/19/08 1:09 PM : Outperform Start Price: $12.48 MYL Score: 0.92

Inside buys

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYL)

Avatar NWTOGME (< 20) Submitted: 6/09/08 7:19 PM : Underperform Start Price: $12.83 MYL Score: 0.74

Z Strong sell

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYL)

Avatar bluedome (< 20) Submitted: 5/14/08 7:30 PM : Outperform Start Price: $11.64 MYL Score: 12.34

Beaten down, shouldn't be hurt even in the


dems nationalize health care, which corporate


america would never let happen anyway.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYL)

Avatar hondo928 (99.79) Submitted: 5/04/08 11:51 PM : Outperform Start Price: $12.97 MYL Score: 0.75

This company has been killed the past year, but is starting to show some signs of life, we shall see what this quarters earnings bring, but I think generic drugs will be much bigger in the future, especially if the government doesn't protect big pharm, but who knows this is somewhat of a gamble, but has a pretty high reward possibility in my opinion.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 81 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 14 of 14  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCarisandCo 67.52 06/13/08 Outperform NS $12.56-5.65%-6.09%+0.44
TrackScottBleier < 20 06/13/08 Outperform 3M $12.59-5.88%-7.23%+1.35
TrackBerkowitz 75.46 05/27/08 Outperform 1Y $12.58-5.80%-8.34%+2.54 Toggle the visibility of 60-Second Pitch and replies
TrackSoros < 20 03/31/08 Outperform NS $11.60+2.16%-4.29%+6.44 Toggle the visibility of 60-Second Pitch and replies
TrackCitigroup 89.76 03/14/08 Outperform NS $11.17+6.09%-4.87%+10.95
TrackPatDorsey 76.30 01/04/08 Outperform 5Y $13.69-13.44%-10.61%-2.83
TrackBofASec 96.28 12/18/07 Outperform NS $13.80-14.13%-13.55%-0.58
TrackBernstein 84.73 11/15/07 Outperform NS $14.27-16.96%-13.82%-3.14
TrackJPMorgan 90.73 10/04/07 Outperform NS $17.21-31.14%-18.04%-13.11
TrackDreman 94.69 09/30/07 Outperform NS $15.96-25.75%-17.22%-8.53 Toggle the visibility of 60-Second Pitch and replies
TrackCreditSuiss 95.12 09/10/07 Outperform NS $15.59-23.99%-13.79%-10.20
TrackUBS 96.25 09/10/07 Outperform NS $15.59-23.99%-13.79%-10.20
TrackMatrix 90.15 11/20/06 Outperform NS $20.67-42.68%-9.94%-32.74
TrackJimCramer 83.36 08/09/06 Underperform 3W $19.75-40.00%-1.05%+38.94

Results 1 - 14 of 14  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEB20 969ms